CLDN11 and movement disorder: Also, a recent study reported that the stop-loss variants in CLDN11 cause hypomyelinating leukodystrophy in patients with HLD22, who exhibit early-onset spastic movement disorders, expressive speech disorders, and eye abnormalities [85].